US5667767A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for use in embolizing blood vessels
Assignee: Micro Therapeutics Inc
•
Filing: 1995-07-27
•
Granted: 1997-09-16
•
Expires: 2015-07-27
Abstract
Abstract Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise an ethylene vinyl alcohol copolymer, a biocompatible solvent and a water insoluble contrasting agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate. Also disclosed are methods for embolizing a blood vessel using the compositions described herein.
Inventors
- 👤 Richard J. Greff
- 👤 Michael L. Jones
- 👤 Scott Evans
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:32
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/08; A61K; A61K49/00; A61K49/04; A61K49/0404; A61K49/0409; A61K49/0414; A61L24/001; A61L24/046; A61L24/06; A61L2430/00; A61L2430/36
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
77 words
A composition comprising: (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer; (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate; (c) from about 52 to about 87.5 weight percent of a biocompatible solvent wherein the weight percent of each of the components is based on the total weight of the complete composition.
Claim 2
Dependent Claim
77 words
A composition comprising: (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer; (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate; (c) from about 52 to about 87.5 weight percent of a biocompatible solvent wherein the weight percent of each of the components is based on the total weight of the complete composition.
Claim 3
Dependent Claim
35 words
The composition according to claim 1 wherein said ethylene vinyl alcohol copolymer comprises from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.
Claim 4
Dependent Claim
12 words
The composition according to claim 2 wherein said biocompatible solvent is DMSO.
Claim 5
Dependent Claim
12 words
The composition according to claim 3 wherein said contrast agent is tantalum.
Claim 6
Dependent Claim
13 words
The composition according to claim 3 wherein said contrast agent is tantalum oxide.
Claim 7
Dependent Claim
13 words
The composition according to claim 3 wherein said contrast agent is barium sulfate.
Claim 8
Independent Claim
109 words
A method for embolizing a blood vessel by injecting into said blood vessel a sufficient amount of an embolizing composition comprising: (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer embolizing agent; (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate; (c) from about 52 to about 87.5 weight percent of a biocompatible solvent wherein the weight percent of each of the components is based on the total weight of the complete composition under conditions wherein a precipitate is formed which embolizes the blood vessel.
Claim 9
Independent Claim
109 words
A method for embolizing a blood vessel by injecting into said blood vessel a sufficient amount of an embolizing composition comprising: (a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer embolizing agent; (b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate; (c) from about 52 to about 87.5 weight percent of a biocompatible solvent wherein the weight percent of each of the components is based on the total weight of the complete composition under conditions wherein a precipitate is formed which embolizes the blood vessel.
Claim 10
Dependent Claim
35 words
The method according to claim 7 wherein said ethylene vinyl alcohol copolymer comprises from about 25 to about 60 mole percent of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.
Claim 11
Dependent Claim
12 words
The method according to claim 8 wherein said biocompatible solvent is DMSO.
Claim 12
Dependent Claim
12 words
The method according to claim 9 wherein said contrast agent is tantalum.
Claim 13
Dependent Claim
13 words
The method according to claim 9 wherein said contrast agent is tantalum oxide.
Claim 14
Dependent Claim
13 words
The method according to claim 9 wherein said contrast agent is barium sulfate.
Claim 15
Dependent Claim
25 words
The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of about 0.05 to 0.3 cc/minute.
Claim 16
Dependent Claim
24 words
The method according to claim 7 wherein the embolizing composition is injected into the blood vessel at a rate of at least 0.6 cc/minute.
Claim 17
Dependent Claim
39 words
The method according to claim 14 wherein the injection rate of at least 0.6 cc/minute is employed to form a filament like mass projecting down stream from the catheter tip for embolizing tumor masses, organs and arteriovenous malformations (AVM).
References Cited (Backward Citations)
US4079124A
Cited
US4631188A
Cited
US4795741A
Cited
US4938763A
Cited
US4938763B1
Cited
US5202352A
Cited
JPH0557014A
Cited
JPH05253283A
Cited
JPH06107549A
Cited
US5443454A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-09-15 | 2001-03-17 | 2001-09-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-09-15 | 2005-03-17 | 2005-09-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-09-15 | 2009-03-17 | 2009-09-16 | $7700.00 | Window Closed / Lapsed |